Junya Ning

Junya Ning

Auto-generated profile, based on publicly available information

Junya Ning

Department of Thyroid and Breast Surgery, Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center, Tianjin, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
JNJunya Ning
Junya Ning
XHXiukun Hou
Xiukun Hou
JHJie Hao
Jie Hao
WZWei Zhang
Wei Zhang
YSYi Shi
Yi Shi
MGMing Gao
Ming Gao

12 January 2018 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
LZLi-Jie Zhang
Li-Jie Zhang
JNJun-Ya Ning
Jun-Ya Ning
JMJunying Miao
Junying Miao
JLJin-Ting Liu
Jin-Ting Liu
BZBaoxiang Zhao
Baoxiang Zhao
A new benzimidazole-hemicyanine-based ratiometric fluorescent probe (ZBM-H) was developed, which showed high selectivity and sensitivity for detecting HClO. Furthermore, ZBM-H with a longer wavelength emission (653 nm), good membrane permeability and less cytotoxicity was successfully used to image the exogenous and endogenous HClO in RAW264.7 cells.

1 January 2023 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
XHXiukun Hou
Xiukun Hou
MTMengran Tian
Mengran Tian
JNJunya Ning
Junya Ning
ZWZhongyu Wang
Zhongyu Wang
FGFengli Guo
Fengli Guo
XZXiangqian Zheng
Xiangqian Zheng
Thyroid cancer has become the most frequent endocrine-related malignancy. Currently, a mounting body of evidences support the clinical strategies for extending the benefit of PARP inhibitors beyond BRCA-mutant cancers. However, the functions and molecular mechanisms of PARP inhibitors in thyroid cancers (TCs) are not fully understood. Here, on the one hand, we revealed that niraparib promotes the accumulation of DNA damage in TCs. On the other hand, we indicated that niraparib inhibits the transcription of DIMT1 through promoting Pol II pausing in a PAR-dependent manner, subsequently leading to a global translation inhibition in TCs. Meanwhile, we found that niraparib activates the NF-κB signaling pathway by inhibiting the PARylation of p65, which decreases its ubiquitination and degradation level through E3 ubiquitin ligase RNF146. Moreover, bortezomib (a small molecule inhibitor of the NF-κB signaling pathway) could significantly enhance the anti-tumor effect of niraparib on TCs in vitro and in vivo. Our findings provide mechanistic supports for the efficacy of PARP inhibitors in cancer cells lacking BRCA-mutant.